110
Views
12
CrossRef citations to date
0
Altmetric
Original Research

Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting

, , , , , , & show all
Pages 1063-1073 | Published online: 23 May 2019

References

  • Collaborators GCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:10100. doi:10.1016/S0140-6736(17)31928-1
  • Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 . GOLD executive summary report. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP28128970
  • Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1:1645–1648.871704
  • Rossi A, Khirani S, Cazzola M. Long-acting β2-agonists (LAB) in chronic obstructive pulmonary disease: efficacy and safety. Int J COPD. 2008;3(4):521–529.
  • Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. doi:10.1016/S0140-6736(16)30069-127203508
  • Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016;375(13):1253–1260. doi:10.1056/NEJMoa160803327593504
  • Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–1036. doi:10.1136/thoraxjnl-2012-20287224130228
  • Yang M, Chen H, Zhang Y, et al. Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis. Inhal Toxicol. 2017;29(5):219–226. doi:10.1080/08958378.2017.134600628714745
  • Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–442. doi:10.1016/S2213-2600(15)00106-X25878028
  • Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47(5):1374–1382. doi:10.1183/13993003.01370-201526917606
  • Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax. 2016;71(2):118–125. doi:10.1136/thoraxjnl-2015-20702126585525
  • Song JH, Lee CH, Kim JW, et al. Clinical implications of blood eosinophil count in patients with non-asthma-COPD overlap syndrome COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2455–2464. doi:10.2147/COPD.S12932128860740
  • Quint JK, Mullerova H, DiSantostefano RL, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open. 2014;4(7):e005540. doi:10.1136/bmjopen-2014-005540
  • Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma. 2006;43(1):75–80. doi:10.1080/0277090050044873816448970
  • Landis SH, Suruki R, Hilton E, Compton C, Galwey NW. Stability of blood eosinophil count in patients with COPD in the UK clinical practice research datalink. Copd. 2017;14(4):382–388. doi:10.1080/15412555.2017.131382728569614
  • National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management. London: National Institute for Health and Care Excellence Publication; 2018.
  • Rothnie KJ, Chandan JS, Goss HG, Mullerova H, Quint JK. Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care. Int J Chron Obstruct Pulmon Dis. 2017;12:1663–1668. doi:10.2147/COPD.S13389128652719
  • Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur Respir J. 2018. doi:10.1183/13993003.02536-2017
  • Nissen F, Morales D, Mullerova H, Smeeth L, Quint JK, Douglas I. Misdiagnosis of COPD in asthma patients in the UK electronic health records (Clinical practice research datalink). A59. Epidemiol Airways Chron Lung Dis. 2017;195:A2026–A2026.
  • Singh D, Kolsum U, Brighling CE, Locantore N, Agusti A, Tal-Singer R. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44:1697–1700. doi:10.1183/09031936.0016241425323230
  • Tashkin DP. Variations in FEV(1) decline over time in chronic obstructive pulmonary disease and its implications. Curr Opin Pulm Med. 2013;19(2):116–124. doi:10.1097/MCP.0b013e32835d8ea423287286
  • Babu KS, Kastelik JA, Morjaria JB. Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. Br J Clin Pharmacol. 2014;78(2):282–300. doi:10.1111/bcp.1233425099256
  • Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255. doi:10.1164/rccm.201310-1863PP Available from: http://hdl.handle.net/10044/1/68961. Accessed April 10, 2019.24383418